Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 12/20 | 0.70 |
| ▸ | TTK | P33981 | 5/20 | 0.70 |
| ▸ | MAPK7 | Q13164 | 6/20 | 0.63 |
| ▸ | DCLK1 | O15075 | 5/20 | 0.63 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.63 |
| ▸ | PLK4 | O00444 | 2/20 | 0.61 |
| ▸ | GAK | O14976 | 1/20 | 0.61 |
| ▸ | STK33 | Q9BYT3 | 1/20 | 0.61 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.61 |
| ▸ | BRD4 | O60885 | 6/20 | 0.57 |
| ▸ | BRDT | Q58F21 | 5/20 | 0.57 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.57 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.56 |
| ▸ | PI4KA | P42356 | 1/20 | 0.55 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.55 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.55 |
| ▸ | TNK1 | Q13470 | 1/20 | 0.55 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.55 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.55 |
| ▸ | DCLK2 | Q8N568 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL619395 | 1.00 | PLK1 (0.70) | PLK1TTKMAPK7DCLK1LRRK2 | |
| SCHEMBL10098797 | 0.92 | MAPK7 (0.65) | PLK1TTKMAPK7DCLK1LRRK2 | |
| SCHEMBL618780 | 0.92 | MAPK7 (0.65) | PLK1TTKMAPK7DCLK1LRRK2 | |
| SCHEMBL619160 | 0.91 | PLK1 (0.59) | PLK1TTKMAPK7DCLK1LRRK2 | |
| SCHEMBL10098790 | 0.91 | PLK1 (0.59) | PLK1TTKMAPK7DCLK1LRRK2 | |
| SCHEMBL10098728 | 0.90 | LRRK2 (0.65) | PLK1TTKMAPK7DCLK1LRRK2 | |
| SCHEMBL619272 | 0.90 | LRRK2 (0.65) | PLK1TTKMAPK7DCLK1LRRK2 | |
| SCHEMBL10098783 | 0.87 | BRD4 (0.73) | PLK1TTKMAPK7DCLK1GAK | |
| SCHEMBL616163 | 0.87 | BRD4 (0.73) | PLK1TTKMAPK7DCLK1GAK | |
| SCHEMBL10098781 | 0.84 | PLK1 (0.69) | PLK1TTKMAPK7DCLK1GAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10570154-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-20170260208-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-09-14 | — | — | US | disclosed |
| US-9701683-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-07-11 | — | — | US | disclosed |
| US-20160347755-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2016-12-01 | — | — | US | disclosed |
| US-9464091-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-20160122357-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2016-05-05 | — | — | US | disclosed |
| US-9266890-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20120040961-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040961-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, BRSK1, TAOK3 | PLK1 109/4885TTK 49/4885MAPK7 263/4885 |
| US-20160122357-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, STK3, BRSK1 | PLK1 110/4885TTK 41/4885MAPK7 253/4885 |
| US-10570154-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders | BRSK2, STK3, BRSK1 | PLK1 110/4885TTK 41/4885MAPK7 253/4885 |
| US-20160347755-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, STK3, BRSK1 | PLK1 117/4885TTK 66/4885MAPK7 263/4885 |
| US-20170260208-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, STK3, BRSK1 | PLK1 110/4885TTK 41/4885MAPK7 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.